KAPA
Kairos Pharma, Ltd. AMEX Listed Sep 16, 2024$0.37
+0.54%
vs $0.37
Mkt Cap $6.8M
52w Low $0.35
1.2% of range
52w High $1.97
50d MA $0.49
200d MA $0.74
P/E (TTM)
-1.2x
EV/EBITDA
—
P/B
1.1x
Debt/Equity
0.0x
ROE
-85.9%
P/FCF
-2.0x
RSI (14)
27.60
ATR (14)
$0.03
Beta
1.98
50d MA
$0.49
200d MA
$0.74
Avg Volume
125.6K
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
CIK (SEC)
Phone
310-948-2356
2355 Westwood Blvd. · Los Angeles, CA 90064 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.02 | -0.07 | -264.3% | 0.56 | -1.3% | +3.6% | +0.3% | +6.7% | -4.4% | -1.9% | — |
| Nov 14, 2025 | AMC | -0.10 | -0.07 | +30.0% | 0.83 | -0.1% | -6.4% | -3.4% | -4.8% | -3.8% | -2.0% | — |
| Aug 12, 2025 | AMC | -0.06 | -0.08 | -33.3% | 1.12 | +6.2% | -4.5% | +15.9% | -3.2% | -2.5% | -6.0% | — |
| Apr 15, 2025 | AMC | -0.05 | -0.08 | -60.0% | 0.98 | +5.7% | -7.8% | +5.8% | -5.0% | -1.9% | -3.9% | — |
| Feb 26, 2025 | AMC | -0.06 | -0.09 | -43.8% | 1.24 | -4.0% | -2.4% | -1.7% | -9.2% | +1.9% | +2.7% | — |
| Nov 14, 2024 | AMC | -0.02 | -0.10 | -400.0% | 2.06 | +0.0% | -24.8% | +10.3% | -14.0% | -0.7% | +2.7% | — |
| Jun 30, 2024 | AMC | — | -0.02 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | AMC | — | -0.03 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.11 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.03 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.02 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.01 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 19 | D. Boral Capital | Maintains | Buy → Buy | — | $0.75 | $0.75 | +0.4% | -4.8% | -3.8% | -2.0% | +8.2% | +0.8% |
| Nov 4 | D. Boral Capital | Maintains | Buy → Buy | — | $1.01 | $1.00 | -1.0% | -14.2% | +8.4% | -7.4% | -2.0% | +8.8% |
| Oct 20 | D. Boral Capital | Maintains | Buy → Buy | — | $1.16 | $1.20 | +3.4% | +0.9% | -2.6% | -7.0% | +2.8% | +0.0% |
| Oct 7 | D. Boral Capital | Maintains | Buy → Buy | — | $1.22 | $1.33 | +9.0% | +0.0% | +7.4% | +0.8% | -12.1% | +4.3% |
| Sep 19 | D. Boral Capital | Maintains | Buy → Buy | — | $1.34 | $1.29 | -3.7% | -9.0% | -5.7% | +0.0% | +4.3% | -5.0% |
| Jul 16 | D. Boral Capital | Maintains | Buy → Buy | — | $1.17 | $1.07 | -8.5% | -6.8% | -6.4% | +5.9% | -6.5% | +2.0% |
| Jun 4 | D. Boral Capital | Maintains | Buy → Buy | — | $0.45 | $0.44 | -2.2% | +15.8% | -3.6% | -5.8% | +19.9% | -4.1% |
| Apr 17 | D. Boral Capital | Maintains | Buy → Buy | — | $0.91 | $0.94 | +3.6% | +5.8% | -5.0% | -1.9% | -3.9% | -0.8% |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $0.92 | $0.97 | +5.3% | +1.6% | -1.7% | -0.1% | +2.3% | +12.8% |
| Mar 20 | D. Boral Capital | Maintains | Buy → Buy | — | $0.94 | $0.92 | -1.9% | +4.3% | +3.1% | -5.7% | +2.9% | -2.0% |
| Feb 26 | D. Boral Capital | Maintains | Buy → Buy | — | $1.14 | $1.16 | +1.8% | +8.8% | -2.4% | -1.7% | -9.2% | +1.9% |
| Feb 18 | D. Boral Capital | Maintains | Buy → Buy | — | $1.37 | $1.36 | -0.7% | -2.9% | -0.8% | +0.8% | -4.5% | -6.3% |
| Feb 12 | D. Boral Capital | Maintains | Buy → Buy | — | $1.35 | $1.35 | +0.0% | +0.7% | +6.6% | -5.5% | -2.9% | -0.8% |
| Jan 22 | D. Boral Capital | Maintains | Buy → Buy | — | $1.59 | $1.60 | +0.6% | +2.5% | -4.3% | -3.8% | +2.0% | -3.3% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $2.21 | $2.12 | -4.1% | -6.8% | -24.8% | +10.3% | -14.0% | -0.7% |
No insider trades available.
8-K
Kairos Pharma, Ltd. -- 8-K Filing
Jun 30
8-K · 8.01
!! High
Kairos Pharma, Ltd. -- 8-K 8.01: Material Event / Announcement
Jun 4
8-K · 8.01
!! High
Kairos Pharma, Ltd. -- 8-K 8.01: Material Event / Announcement
May 18
8-K · 8.01
!! High
Kairos Pharma, Ltd. -- 8-K 8.01: Material Event / Announcement
Kairos Pharma (KAPA) has agreed to acquire CL-273 from Celyn through a binding term sheet, potentially expanding its drug development pipeline.
Mar 2
8-K · 8.01
!! High
Kairos Pharma, Ltd. -- 8-K 8.01: Material Event / Announcement
Kairos Pharma signed a letter of intent to acquire two clinical-stage lung cancer drug candidates from privately-held Celyn Therapeutics, expanding its oncology pipeline.
Feb 26
Valuation
Market Cap
$6.8M
Enterprise Value
$2.3M
P/E (TTM)
-1.24x
Forward P/E
—
PEG Ratio
-0.08x
P/B
1.08x
P/S
—
P/FCF
-1.98x
EV/EBITDA
—
Shares Out
18.4M
Financials (TTM)
Revenue
$0
Net Income
-$5.8M
EBITDA
-$5.7M
Free Cash Flow
-$3.4M
Op Cash Flow
-$3.4M
EPS Basic
$-0.30
EPS Diluted
$-0.30
EPS Forward
$-0.38
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$6.5M
Total Liab.
$199K
Total Equity
$6.3M
Cash
$4.5M
LT Debt
$0
Book Value/Sh
$0.34
Debt/Equity
0.00x
Current Ratio
27.07
Quick Ratio
27.07
Returns & Growth
ROE
-85.9%
ROA
-83.3%
ROIC
-87.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
-30.4%
Price Returns
2W
-19.0%
1M
-19.9%
3M
-40.3%
6M
-49.2%
12M
-43.1%
Technicals
52W High
$1.97
52W Low
$0.35
50d MA
$0.49
200d MA
$0.74
RSI (14)
27.60
ATR (14)
$0.03
Beta
1.98
Avg Volume
126K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 5:11pm
· Source: financialmodelingprep.com